Navigation Links
US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
Date:12/17/2007

SAN ANTONIO, Dec. 17 /PRNewswire/ -- A leading cancer physician and researcher affiliated with US Oncology Research, an established community-based research network specializing in Phase I - Phase IV cancer clinical trials, presented findings on a Phase II trial conducted to increase pathologic complete response (pCR) and discover a baseline tumor gene expression profile associated with subsequent pCR for patients with stage 2 and 3 breast cancer.

The study results were presented in a poster session by Frankie Ann Holmes, M.D., of Texas Oncology, P.A.-Houston, associate chair of US Oncology's Breast Cancer Research Committee and a member of the US Oncology Network.

Dr. Holmes' was one of two poster presentations presented December 13-16 at the 30th annual San Antonio Breast Cancer Symposium by physicians affiliated with US Oncology, Inc., which supports one of the nation's largest oncology treatment and research networks.

"The future is now," said Dr. Frankie Ann Holmes, lead investigator for the trial. "The future of breast cancer is identification of the molecular mistakes in the tumor, then tailoring treatment to attack those mistakes. In the past, this could only be done at academic medical centers. Our trial showed that this can be done in a local oncologist's office."

The study, titled "Development of a genomic tool to predict pathologic complete remission in a community-based, preoperative, Phase II trial of 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel-capecitabine for stage 2, 3 breast cancer," was conducted among women with stage 2-3 breast cancer who underwent pretreatment fine needle aspiration (FNA) preserved in RNAlater(R) and shipped to Lajos Pusztai, M.D., Associate Professor at M.D. Anderson Cancer Center.

Tissue from 34 patients was sent for chemoresponse testing with ChemoFx(R). After FNA, FEC100 given as 5-FU 500 mg/m2, epirubicin 100 mg/m2 (75 mg/m2 if HER2+: "FEC75 +H"), and cycloph
'/>"/>

SOURCE US Oncology
Copyright©2007 PR Newswire.
All rights reserved

13

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... , WALTHAM, Mass., Dec. 3 Dec...ch and advisory firms focusing on pharmaceutical a...abetes drug market in Brazil will grow from $417 m...ted 15 percent annual growth rate is attributed to...increased use of new generation antidiabetics such...
(Date:12/3/2009)...SAN DIEGO, Dec. 3 Amira Pharmace...a from a Phase 1 clinical study of AM461, the Comp...(also known as CRTH2) receptor. ,, The interi...rmacodynamic (PD) effect can be achieved with AM46...strates a good safety profile. AM461 is a back-up...
(Date:12/3/2009)..., NANJING, China, Dec. 3 /PRNewswire-Asia/ ..."Company") (NYSE: SCR ), a leading pharmaceutica...turing, and marketing of branded,generic and propr...at China,s,State Food and Drug Administration ("SF...nto quality issues regarding human use rabies vacc...
Breaking Medicine Technology:Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen 2Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen 3Scientists demonstrate importance of niche differences in biodiversity 9554 1Scientists demonstrate importance of niche differences in biodiversity 9554 2Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 54365 1Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 54365 2Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 1Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 2Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 54361 3
...n who adhere to a traditional Mediterranean diet -...le grains and fish -- are at a lower risk for stro...y published this week in Circulation: Journal... . , , The research, led by Simmons College Nut...se diets most closely resembled the Mediterranean ...
...ruary 17 Sanofi Pasteur, the,vaccines division of...NY),announced today that it is sponsoring a phase ... difficile, which is among the most common causes ... America. , The trial currently conducted in t...efficacy of sanofi pasteur,s C. difficile candidat...
Other Medicine Technology:Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet 2Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 2Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 4Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 5
(Date:12/3/2009)...Newswire/ -- The American Medical Association (AMA...Court for the Southern District of New York has gr...osed $350 million settlement that would resolve a ..., The action brought by the AMA, Medical Societ...cal Association, along with several other plaintif...
(Date:12/3/2009)...nimally invasive procedures, study finds , ...lly fatal blood clots after surgery are a much gre...ish study finds. , "What is most striking is th...much longer than people have thought," said Dr. Ja...ity of Oxford and a leader of the team reporting t...
(Date:12/3/2009)...ing of diabetes, cardiovascular disease, researche...ews) -- Pregnant women who develop gestational glu...isk for metabolic syndrome three months after they...ucose intolerance is less severe than gestational ... factors (including high blood pressure, obesity a...
(Date:12/3/2009)...hether they cause brain cancer, , , THU...nes cause brain cancer has been a subject of ongoi...nce suggesting that they don,t. , A 30-year exa...inavia found no substantial change in prevalence e...ing to the report in the Dec. 3 online edition of ...
(Date:12/3/2009)...The day has come. Eight months in the planning, de...re RN organizations will gather in Phoenix Monday,... 150,000-member National Nurses United, the larges...story. ,, AFL-CIO President Richard Trumka will... will chart a course for the building of a more po...
Breaking Medicine News(10 mins):Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2Health News:Blood Clot Threat After Surgery Worse Than Thought 2Health News:Blood Clot Threat After Surgery Worse Than Thought 3Health News:Blood Sugar Intolerance May Predict Postpartum Ills 2Health News:No Increase in Brain Tumors Seen From Cell Phones 2Health News:No Increase in Brain Tumors Seen From Cell Phones 3Health News:RN SuperUnion Founding Convention Opens Monday 2
..., 2009 -- The device looks deceptively simple a p...ket with a spigot but Vinka Craver believes it ca...nt professor of civil and environmental engineerin... becomes safe to drink., "More than one billion ...
...National Safety Council will host a National Poiso... National Poison Prevention Week Council, Tuesday,... Club in Washington, D.C. The event will feature a...duation. Other speakers will include: , , , ,...
...etary of Labor Hilda L. Solis today announced the ...king (ANPRM) for occupational exposure to food fla...ill facilitate the Labor Department,s Occupational...y fatal lung disease associated with such an expos...
... Medical, Inc., manufacturer of the CryoSpray Abla...f its newly redesigned Web site ( www.CSAmedical.c.../prnh/20080721/NEM114LOGO ) , , The Web site fea...e and destroy unwanted tissue in the body. The upd...
...ntertechPira,s 2009 Applications of High-Power Sem...er 15 - 17, 2009 in San Diego, CA , ... Applications of High-Power Semiconductor Lasers (...PSL 2009 will be divided into sectors reflecting i...
..., 2009 A new study published in Epilepsia finds... as high in people with epilepsy compared to the g...al minorities have seven times the odds of depress...ng mental healthcare services. , Data from the 20...
Other Medicine News:Health News:Engineer helps poor in developing nations purify drinking water 2Health News:NSC Hosts National Poison Prevention Week News Conference, Tuesday, March 17 2Health News:U.S. Secretary of Labor Hilda L. Solis takes action to prevent workers' exposure to food flavorings chemical 2Health News:CSA Medical, Inc. Announces Launch of New Web Site for Spray Cryotherapy 2Health News:Call for Presentations: Applications of High-Power Semiconductor Lasers Conference & Exhibit 2Health News:Depression twice as likely in seizure sufferers 2
5.5mm Trephine Handle
10.0mm Calibrated Trephine Handle
8.25mm Calibrated Trephine Handle
6.5mm Calibrated Trephine Handle
Medicine Products: